Tenaya Therapeutics reported revenue of $1.11M and net income of -$43.39M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 26.90M | 17.73M | 41.31M | 41.36M | 41.37M | 44.82M | 66.87M | 67.87M | 68.11M | 68.33M | 78.52M | 78.89M | 79.22M | 86.54M | 109.87M | 162.98M | 166.51M | 152.97M | 217.00M | 224.23M | |||||
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 0.23M | 1.11M | |||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 12.94M | 20.95M | 24.16M | 20.88M | 23.76M | 25.75M | 25.61M | 26.48M | 23.09M | 22.86M | 25.05M | 22.65M | 20.35M | 18.69M | 21.08M | 17.37M | 15.36M | 14.80M | 14.84M | 16.60M | |||||
| Selling, General & AdministrativeSG&A | 5.36M | 5.21M | 7.00M | 7.74M | 7.54M | 8.80M | 8.12M | 8.63M | 7.83M | 8.58M | 8.71M | 8.17M | 6.36M | 5.96M | 6.46M | 6.71M | 5.57M | 5.98M | 5.45M | 5.41M | |||||
| Other Operating ExpensesOther Opex | -1.37M | ||||||||||||||||||||||||
| Operating ExpensesOpex | 18.30M | 26.16M | 31.15M | 28.62M | 31.30M | 34.55M | 33.72M | 35.10M | 30.92M | 31.45M | 33.76M | 30.82M | 26.71M | 24.65M | 27.54M | 24.08M | 20.94M | 20.77M | 20.29M | 45.20M | |||||
| Operating IncomeOp. Inc | -18.30M | -26.16M | -31.15M | -28.62M | -31.30M | -34.55M | -33.72M | -35.10M | -30.92M | -31.45M | -33.76M | -30.82M | -26.71M | -24.65M | -27.54M | -24.08M | -20.94M | -20.77M | -20.07M | -44.09M | |||||
| EBIT | -18.30M | -26.16M | -31.15M | -28.62M | -31.30M | -34.55M | -33.72M | -35.10M | -30.92M | -31.45M | -33.76M | -30.82M | -26.71M | -24.65M | -27.54M | -24.08M | -20.94M | -20.77M | -20.07M | -44.09M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -0.02M | -0.18M | -0.49M | 0.22M | 0.60M | 1.04M | 1.97M | 1.84M | 1.78M | 1.47M | 1.45M | 1.39M | 1.08M | 0.81M | 0.64M | 0.81M | 0.66M | 0.57M | 0.79M | 0.70M | |||||
| Other Non Operating IncomeOther Non Op Inc. | 0.01M | -0.05M | -0.00M | 0.01M | -0.00M | 0.01M | -0.00M | 0.00M | 0.04M | 0.08M | -0.00M | -0.00M | 0.00M | 0.04M | -0.02M | 0.00M | 0.03M | -0.00M | |||||||
| Non Operating IncomeNon Op. Inc. | 0.04M | 0.01M | 0.10M | 0.22M | 0.60M | 1.03M | 1.99M | 1.83M | 1.78M | 1.51M | 1.53M | 1.39M | 1.08M | 0.82M | 0.67M | 0.80M | 0.66M | 0.60M | 0.79M | 0.69M | |||||
| Net income details | |||||||||||||||||||||||||
| EBT | -18.26M | -26.15M | -31.06M | -28.40M | -30.70M | -33.52M | -31.74M | -33.27M | -29.14M | -29.93M | -32.23M | -29.43M | -25.63M | -23.84M | -26.86M | -23.28M | -20.27M | -20.18M | -19.27M | -43.39M | |||||
| Profit After TaxPAT | -18.29M | -26.26M | -31.06M | -28.40M | -30.72M | -33.13M | -31.74M | -33.27M | -29.14M | -29.95M | -32.23M | -29.43M | -25.63M | -23.83M | -26.86M | -23.28M | -20.27M | -20.18M | -19.27M | -43.39M | |||||
| Income from Continuing OperationsIncome (Continuing) | -18.26M | -26.15M | -31.06M | -28.40M | -30.70M | -33.52M | -31.74M | -33.27M | -29.14M | -29.93M | -32.23M | -29.43M | -25.63M | -23.84M | -26.86M | -23.28M | -20.27M | -20.18M | -19.27M | -43.39M | |||||
| Consolidated Net IncomeConsol Net Inc. | -18.26M | -26.15M | -31.06M | -28.40M | -30.70M | -33.52M | -31.74M | -33.27M | -29.14M | -29.93M | -32.23M | -29.43M | -25.63M | -23.84M | -26.86M | -23.28M | -20.27M | -20.18M | -19.27M | -43.39M | |||||
| Income towards Parent CompanyParent Net Inc | -18.26M | -26.15M | -31.06M | -28.40M | -30.70M | -33.52M | -31.74M | -33.27M | -29.14M | -29.93M | -32.23M | -29.43M | -25.63M | -23.84M | -26.86M | -23.28M | -20.27M | -20.18M | -19.27M | -43.39M | |||||
| Net Income towards Common StockholdersNet Income | -18.26M | -26.15M | -31.06M | -28.40M | -30.70M | -33.52M | -31.74M | -33.27M | -29.14M | -29.93M | -32.23M | -29.43M | -25.63M | -23.84M | -26.86M | -23.28M | -20.27M | -20.18M | -19.27M | -43.39M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.68 | -1.47 | -0.75 | -0.69 | -0.74 | -0.75 | -0.43 | -0.45 | -0.39 | -0.41 | -0.40 | -0.34 | -0.30 | -0.28 | -0.24 | -0.14 | -0.12 | -0.13 | -0.09 | -0.20 | |||||
| EPS (Diluted) | -0.68 | -1.47 | -0.75 | -0.69 | -0.74 | -0.75 | -0.43 | -0.45 | -0.39 | -0.41 | -0.40 | -0.34 | -0.30 | -0.28 | -0.24 | -0.14 | -0.12 | -0.13 | -0.09 | -0.20 | |||||
| Shares Outstanding | 26.90M | 17.73M | 41.27M | 41.30M | 41.36M | 44.82M | 73.10M | 73.40M | 73.92M | 73.79M | 80.98M | 85.71M | 86.16M | 84.82M | 109.87M | 162.79M | 163.35M | 152.97M | 216.88M | 217.57M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 26.90M | 17.73M | 41.27M | 41.30M | 41.36M | 44.82M | 73.10M | 73.40M | 73.92M | 73.79M | 80.98M | 85.71M | 86.16M | 84.82M | 109.87M | 162.79M | 163.35M | 152.97M | 216.88M | 217.57M | |||||
| EBITDA | -18.30M | -26.16M | -31.15M | -28.62M | -31.30M | -34.55M | -33.72M | -35.10M | -30.92M | -31.45M | -33.76M | -30.82M | -26.71M | -24.65M | -27.54M | -24.08M | -20.94M | -20.77M | -20.07M | -44.09M |